Molecular docking studies further supported these findings by identifying potential anti-UCEC/COVID-19 pharmacological biotargets of PLB, such as mitogen-activated protein kinase 3 (MAPK3), urokinase-type plasminogen activator (PLAU), and tumour necrosis factor (TNF) [125]. The gene discussed is PLAU; the disease is COVID-19.